ArticleBMC microbiology2026
Integrated analysis of human-mouse gut microbiota in RSV infection based on machine learning.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children, but effective treatment options remain limited. The gut-lung axis, which highlights the role of gut microbiota in regulating respiratory immunity, provides new opportunities for developing probiotic-based therapies. However, existing studies on RSV-associated gut microbiota are often small-scale and lack systematic integration. To address this gap, we conducted a comprehensive machine learning-based analysis of gut microbiota data from RSV-infected children and mice, integrating five public datasets comprising 319 samples (154 children, 165 mice).
resultsPediatric samples were divided into control, infected, and recovery groups, while mouse samples included control and infected groups. Microbial diversity analysis revealed RSV infection disrupted gut microbiota structure in children, with reduced α-diversity in the infected group and significant β-diversity differences among groups (P < 0.001). Mice exhibited higher α-diversity than children, with distinct dominant taxa: Bifidobacteriaceae and Escherichia-Shigella prevailed in children, whereas Lachnospiraceae and Ligilactobacillus dominated in mice. Using 13 machine learning algorithms, we developed disease-prediction models at the family and genus levels, achieving superior performance in pediatric data (maximum AUC = 0.952) compared to mouse data. Cross-species analysis identified 62 family-level and 54 genus-level high-importance taxa (e.g., Bacteroidaceae, Bifidobacteriaceae, Romboutsia) shared between the two host species, accounting for 36%-60% of feature microbiota. Functional profiles showed significant remodeling during recovery, characterized by the loss of native functions such as D-arabinitol 4-dehydrogenase but acquisition of novel metabolic capabilities, including fructan biosynthesis pathways. Notably, Bacteroidaceae contributed extensively to differential functions, particularly short-chain fatty acid metabolism via propionyl-CoA carboxylase, highlighting its role in gut-lung immune regulation.
conclusionThese findings provide the first cross-species machine learning analysis of RSV-associated, though not necessarily RSV-specific, gut microbiota, offering insights into gut-lung axis mechanisms and identifying potential targets for probiotic-based interventions in RSV management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.